Key takeaways

• Semax vs Selank contrasts a melanocortin-lineage peptide with a tuftsin-lineage one.
• Both are seven amino acids long and both use a C-terminal Pro-Gly-Pro tail for protease resistance.
• Semax is Met-Glu-His-Phe-Pro-Gly-Pro, built on the ACTH(4-7) fragment.
• Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, built on the tuftsin tetrapeptide.
• Research on Semax centres on BDNF, NGF and TrkB signalling; research on Selank centres on GABAergic and neuroimmune pathways.
• Neither carries the hormonal activity of its parent molecule, which is the point of the modification.
• Both are lyophilized, third-party tested, and supplied for in vitro research only.

What the Semax vs Selank comparison is about

Regulatory peptides are short sequences that modulate signalling systems rather than acting as classical single-target agonists. The practical problem with using them experimentally is that short peptides are cleaved rapidly. Russian peptide chemistry solved this in both cases the same way, by appending Pro-Gly-Pro, a tripeptide that markedly slows enzymatic degradation while leaving the active fragment intact.

So the Semax vs Selank question is not about which stabilisation strategy is better — they share one. It is about which biological system the stabilised fragment engages.

• Shared design: a short active fragment plus a C-terminal Pro-Gly-Pro stabiliser.
• Shared length: seven residues each.
• Semax parent: adrenocorticotropic hormone, fragment 4-10.
• Selank parent: tuftsin, a fragment of the immunoglobulin G heavy chain.
• Removed liability: Semax lacks steroidogenic corticotropic action; Selank lacks the instability of native tuftsin.
• Physical form: both supplied as white lyophilized powders requiring reconstitution.

Semax vs Selank: mechanism of action

The two peptides diverge sharply once past the shared architecture. Semax acts primarily on neurotrophic and monoaminergic systems. Selank acts on inhibitory neurotransmission and immune signalling. Neither engages a single receptor cleanly, which is characteristic of regulatory peptides generally: the observed effects are shifts in the balance of several systems rather than the saturation of one target.

• Semax raises BDNF protein and TrkB phosphorylation in hippocampal tissue in rodent work.
• Exon III BDNF and TrkB mRNA rise alongside the protein-level changes.
• Semax also modulates monoaminergic tone, which is why attention and learning paradigms feature heavily.
• Neuroprotective endpoints appear in cerebral ischaemia-reperfusion models.
• Selank alters expression of genes governing GABAergic neurotransmission in cortical tissue and cell lines.
• Its anxiolytic profile in animal models has been compared with benzodiazepine reference compounds.
• Selank additionally shows enkephalinergic activity, slowing enkephalin degradation.
• The tuftsin lineage brings neuroimmune readouts, including cytokine and interferon endpoints.

The neurotrophic arm is documented in work showing Semax regulates BDNF and TrkB expression in the rat hippocampus, and the inhibitory arm in work on Selank and the expression of genes involved in GABAergic neurotransmission.

Semax vs Selank compared

The table sets out the Semax vs Selank differences that matter when selecting a compound for a model.

Why the Semax vs Selank differences matter in practice:

• Neurotrophic and GABAergic readouts require different assays and different timescales.
• A cognition paradigm will not detect an anxiolytic-type effect, and vice versa.
• Selank’s immune activity makes immune status a variable in its models, not background.
• Semax’s monoaminergic component overlaps with stimulant-adjacent paradigms and needs matching controls.
• Shared Pro-Gly-Pro chemistry means shared handling, but not shared endpoints.

Semax vs Selank research applications

Published preclinical work on Semax vs Selank clusters into distinct, largely non-overlapping areas:

• Learning and memory paradigms: acquisition and retention tasks in rodent models.
• Neurotrophin signalling: BDNF, NGF and TrkB expression and phosphorylation.
• Ischaemia models: protein-expression profiling after cerebral ischaemia-reperfusion.
• Anxiety-related behaviour: elevated-plus-maze and comparable rodent paradigms.
• GABAergic gene expression: transcript panels in cortical tissue and neuroblastoma lines.
• Neuroimmune crosstalk: cytokine and interferon readouts tied to the tuftsin lineage.
• Analytical work: HPLC and LC-MS confirmation of heptapeptide identity and purity.

Both compounds have an unusually long research history for peptides of this class, and much of it predates modern reporting standards, so study quality varies considerably. A clinical literature also exists for both, largely from Russian research groups, and it is referenced here only as scientific context. It does not alter the status of the material supplied on this site, which is a research reagent and nothing else.

Why Semax vs Selank is often studied as a pair

The two peptides are frequently discussed together because they came out of the same laboratory tradition and share a stabilisation motif, not because they are interchangeable. Studied side by side, they let a research design separate neurotrophic effects from inhibitory-neurotransmission effects using compounds matched for length, chemistry and handling.

• Matched size and stability remove two confounds from a two-arm comparison.
• Divergent mechanisms mean each acts as a partial specificity control for the other.
• Overlapping behavioural readouts still require separate task designs to interpret.
• Neither compound should be assumed to share the other’s time course.
• Our Semax research guide and Selank research guide cover each compound individually.

Handling, reconstitution, and quality verification

Handling is one area where the Semax vs Selank distinction disappears: both are short lyophilized peptides with the same practical requirements.

• Store the sealed lyophilized vial refrigerated, or frozen long-term, protected from light.
• Bring the vial to room temperature before opening to avoid condensation on the cake.
• Reconstitute with bacteriostatic or sterile water down the vial wall, never onto the powder.
• Swirl gently; vortexing shears peptide chains and promotes aggregation.
• Refrigerate the reconstituted solution and use within the window your protocol validates.
• Aliquot once and thaw each aliquot once to avoid repeated freeze-thaw cycles.
• Record lot, reconstitution date, diluent and concentration for traceability.

Both compounds are supplied at greater than 99% HPLC-verified purity, and COA validity can be confirmed independently at freedomdiagnosticstesting.com using the Accession Number, Client ID or Search Code shown in the product images. For what those documents establish, see our guide to peptide purity, HPLC and mass spectrometry.

Considerations for experimental design

Most of the variables below apply to both compounds, but the first two are where a Semax vs Selank design most often goes wrong.

• Match the assay to the pathway: neurotrophic and GABAergic endpoints are not substitutes.
• Immune status: a controlled variable in any Selank model, given the tuftsin lineage.
• Solution age: treat time-since-reconstitution as a controlled variable.
• Timescale: transcript-level changes and behavioural changes resolve on different schedules.
• Vehicle controls: essential where behavioural readouts are sensitive to handling stress.
• Documentation: lot-level COA references make a result reproducible elsewhere.

Treated carefully, the Semax vs Selank pairing is a useful piece of experimental architecture: two compounds identical in most of the ways that usually confound a comparison, and different in precisely the way being tested.

Frequently asked questions

What is the difference between Semax vs Selank?

They share a design but not a lineage. Semax is a heptapeptide built on the ACTH(4-7) melanocortin fragment and is studied for BDNF, NGF and TrkB neurotrophic signalling, while Selank is a heptapeptide built on the immunopeptide tuftsin and is studied for GABAergic, enkephalinergic and neuroimmune endpoints.

Why do both peptides end in Pro-Gly-Pro?

The C-terminal Pro-Gly-Pro tripeptide is a stabilising modification that confers strong resistance to enzymatic degradation. Without it, both parent fragments would be cleaved too quickly to produce a measurable signal in most research models, so the same solution was applied to two different active sequences.

Which peptide is studied for cognition and which for anxiety?

Semax dominates the learning, memory and neuroprotection literature, reflecting its neurotrophic and monoaminergic activity. Selank appears mainly in anxiety-related behavioural paradigms and GABAergic gene-expression work. The Semax vs Selank split here is one of research emphasis in published models, not a statement about effects in people.

Can Semax and Selank be studied together?

They are often examined as a pair because they are matched for length, chemistry and handling while diverging in mechanism, which makes each a partial specificity control for the other. Combined-arm designs still need single-compound arms if any effect is to be attributed to one peptide.

Are Semax and Selank approved for human use?

No. Both compounds supplied by NeuroPept Labs are sold strictly for in vitro and laboratory research and are not approved, intended or supplied for human or veterinary consumption. They are not drug products and nothing in this article should be read as medical advice or as a recommendation for use in people.

How should these peptides be stored and reconstituted?

Keep the sealed lyophilized vial refrigerated or frozen and protected from light, then bring it to room temperature before opening. Reconstitute with bacteriostatic or sterile water down the vial wall, swirl rather than shake, refrigerate the resulting solution, and aliquot to avoid repeated freeze-thaw cycles.